Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283069891> ?p ?o ?g. }
- W4283069891 endingPage "7" @default.
- W4283069891 startingPage "1" @default.
- W4283069891 abstract "Background. Over the last few years, the role of PDL1/PD-1 in pancreatic cancer development has received increasing attention, and this article is aimed at opening up new ideas for the medicine-based treatment of pancreatic cancer. Aims. To investigate the efficacy and safety of PDL1/PD-1 inhibitors versus FOLFIRINOX regimen in the treatment of advanced pancreatic cancer and its impact on patient survival and to provide a reference basis for clinical treatment of pancreatic cancer. Materials and Methods. The 116 pancreatic cancer patients treated in our hospital from September 2019 to September 2021 were selected and divided into 58 cases each in the (instance of watching, noticing, or making a statement) group and the comparison group according to the method based on random number table. The comparison group was treated with FOLFIRINOX, and the group was treated with PDL1/PD-1 stopper. The effectiveness, safety, and hit/effect on survival of the patients in the two groups were compared. Results. The median chemotherapy cycle for all patients was 4 (1-6), and the combined objective remission rate (0RR) was 36% and the disease control rate (DCR) was 80% after no chemotherapy in 116 patients, with 37.5% 0RR and 81.3% DCR in the observation group and 33.3% 0RR and 77.8% DCR in the comparison group. The greatest number of all patients reached SD, 44%; in the observation group, 43.8%; and in the comparison group, 44.5%. The rate of adverse reactions such as hematological toxicity, neutropenia, anemia, thrombocytopenia, nonhematological toxicity, vomiting, fatigue, infection, diarrhea, intestinal obstruction, and peripheral neuropathy was lower in 10.3% of patients in the observation group than in 25.8% of patients in the comparison group, which was significantly different by <math xmlns=http://www.w3.org/1998/Math/MathML id=M1> <msup> <mrow> <mi>χ</mi> </mrow> <mrow> <mn>2</mn> </mrow> </msup> </math> test ( <math xmlns=http://www.w3.org/1998/Math/MathML id=M2> <mi>P</mi> <mo><</mo> <mn>0.05</mn> </math> ). The median progression-free survival curve of the two groups was 19 months in the comparison group and 22 months in the observation group. The progression-free survival in the observation group was significantly higher than that in the comparison group, and there was a statistically significant difference between the two groups ( <math xmlns=http://www.w3.org/1998/Math/MathML id=M3> <mi>P</mi> <mo><</mo> <mn>0.05</mn> </math> ). Conclusion. PDL1/PD-1 inhibitors in combination with FOLFIRINOX regimens have shown longer survival than treatment with FOLFIRINOX regimens for pancreatic cancer patients, with reliable clinical efficacy, tolerable adverse effects, and a high safety profile for patients." @default.
- W4283069891 created "2022-06-19" @default.
- W4283069891 creator A5029533472 @default.
- W4283069891 creator A5033491568 @default.
- W4283069891 creator A5061112732 @default.
- W4283069891 creator A5066665900 @default.
- W4283069891 date "2022-06-18" @default.
- W4283069891 modified "2023-09-26" @default.
- W4283069891 title "Efficacy, Safety, and Impact on Patient Survival of PDL1/PD-1 Inhibitors versus FOLFIRINOX Regimens for Advanced Pancreatic Cancer" @default.
- W4283069891 cites W2109485845 @default.
- W4283069891 cites W2513200835 @default.
- W4283069891 cites W2619512349 @default.
- W4283069891 cites W2743061229 @default.
- W4283069891 cites W2754597397 @default.
- W4283069891 cites W2756648224 @default.
- W4283069891 cites W2772391116 @default.
- W4283069891 cites W2782998220 @default.
- W4283069891 cites W2794577178 @default.
- W4283069891 cites W2883594834 @default.
- W4283069891 cites W2888367509 @default.
- W4283069891 cites W2925030036 @default.
- W4283069891 cites W2948046941 @default.
- W4283069891 cites W2967658120 @default.
- W4283069891 cites W2987513521 @default.
- W4283069891 cites W2993895135 @default.
- W4283069891 cites W2997645856 @default.
- W4283069891 cites W3021023953 @default.
- W4283069891 cites W3030731299 @default.
- W4283069891 cites W3036745420 @default.
- W4283069891 cites W3045667712 @default.
- W4283069891 cites W3093533116 @default.
- W4283069891 cites W3123099520 @default.
- W4283069891 cites W3127468120 @default.
- W4283069891 cites W3129357027 @default.
- W4283069891 cites W3154654785 @default.
- W4283069891 cites W3162949857 @default.
- W4283069891 cites W3164487428 @default.
- W4283069891 cites W3173283805 @default.
- W4283069891 cites W3197343769 @default.
- W4283069891 cites W4225742880 @default.
- W4283069891 cites W4249980792 @default.
- W4283069891 doi "https://doi.org/10.1155/2022/5430720" @default.
- W4283069891 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35761841" @default.
- W4283069891 hasPublicationYear "2022" @default.
- W4283069891 type Work @default.
- W4283069891 citedByCount "1" @default.
- W4283069891 countsByYear W42830698912023 @default.
- W4283069891 crossrefType "journal-article" @default.
- W4283069891 hasAuthorship W4283069891A5029533472 @default.
- W4283069891 hasAuthorship W4283069891A5033491568 @default.
- W4283069891 hasAuthorship W4283069891A5061112732 @default.
- W4283069891 hasAuthorship W4283069891A5066665900 @default.
- W4283069891 hasBestOaLocation W42830698911 @default.
- W4283069891 hasConcept C121608353 @default.
- W4283069891 hasConcept C126322002 @default.
- W4283069891 hasConcept C141071460 @default.
- W4283069891 hasConcept C143998085 @default.
- W4283069891 hasConcept C197934379 @default.
- W4283069891 hasConcept C2776694085 @default.
- W4283069891 hasConcept C2777063308 @default.
- W4283069891 hasConcept C2777148230 @default.
- W4283069891 hasConcept C2780210213 @default.
- W4283069891 hasConcept C2780258809 @default.
- W4283069891 hasConcept C2780962732 @default.
- W4283069891 hasConcept C2781413609 @default.
- W4283069891 hasConcept C526805850 @default.
- W4283069891 hasConcept C71924100 @default.
- W4283069891 hasConceptScore W4283069891C121608353 @default.
- W4283069891 hasConceptScore W4283069891C126322002 @default.
- W4283069891 hasConceptScore W4283069891C141071460 @default.
- W4283069891 hasConceptScore W4283069891C143998085 @default.
- W4283069891 hasConceptScore W4283069891C197934379 @default.
- W4283069891 hasConceptScore W4283069891C2776694085 @default.
- W4283069891 hasConceptScore W4283069891C2777063308 @default.
- W4283069891 hasConceptScore W4283069891C2777148230 @default.
- W4283069891 hasConceptScore W4283069891C2780210213 @default.
- W4283069891 hasConceptScore W4283069891C2780258809 @default.
- W4283069891 hasConceptScore W4283069891C2780962732 @default.
- W4283069891 hasConceptScore W4283069891C2781413609 @default.
- W4283069891 hasConceptScore W4283069891C526805850 @default.
- W4283069891 hasConceptScore W4283069891C71924100 @default.
- W4283069891 hasLocation W42830698911 @default.
- W4283069891 hasLocation W42830698912 @default.
- W4283069891 hasLocation W42830698913 @default.
- W4283069891 hasOpenAccess W4283069891 @default.
- W4283069891 hasPrimaryLocation W42830698911 @default.
- W4283069891 hasRelatedWork W1975191131 @default.
- W4283069891 hasRelatedWork W2599910524 @default.
- W4283069891 hasRelatedWork W2736952847 @default.
- W4283069891 hasRelatedWork W2896815895 @default.
- W4283069891 hasRelatedWork W3045328550 @default.
- W4283069891 hasRelatedWork W3154040450 @default.
- W4283069891 hasRelatedWork W3177534832 @default.
- W4283069891 hasRelatedWork W3196960728 @default.
- W4283069891 hasRelatedWork W332524067 @default.
- W4283069891 hasRelatedWork W4307429747 @default.
- W4283069891 hasVolume "2022" @default.
- W4283069891 isParatext "false" @default.